Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.48 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29559621 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL18818104 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL26740947 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL22897598 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL8802746 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL30150324 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL11781255 | 0.82 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL27498443 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL16073146 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL10304814 | 0.80 | CYP2D6 (0.50) | MEN1KMT2ABLMP2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249888-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-2970176-B1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-2970176-B1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230077362-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230002790-A1 | POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-3998858-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | Corteva Agriscience LLC (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114072000-A | Molecules having certain pesticidal effects and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
| WO-2021011722-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| CN-101663283-A | Quinoxaline compounds and use thereof | MERCK SERONO SA | 2010-03-03 | — | — | CN | disclosed |
| EP-2118076-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | Merck Serono S.A. (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2007064797-A2 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | PTGIR, S1PR1, TBXA2R | ALDH1A1 1333/4885MEN1 2449/4885KMT2A 2192/4885 |
| US-20230077362-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | ALDH1A1 150/4885MEN1 486/4885KMT2A 2385/4885 |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | ALDH1A1 577/4885MEN1 927/4885KMT2A 3444/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | ALDH1A1 3433/4885MEN1 1750/4885KMT2A 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.